Metastatic Prostate Cancer Global Market Report 2025

Description

Metastatic prostate cancer is a severe stage of prostate cancer where cancer cells have spread from the prostate gland to other areas of the body, including bones, lymph nodes, or distant organs. This stage marks the progression of the disease beyond the prostate, helping guide treatment decisions aimed at slowing the spread, relieving symptoms, and improving survival outcomes.

The primary treatment options for metastatic prostate cancer include chemotherapy, immunotherapy, hormonal therapy, radiation therapy, and other methods. Chemotherapy employs potent drugs to target and destroy fast-growing cells, including cancer cells. It can be administered through various routes, such as oral, parenteral, intravenous, intrathecal, intraperitoneal, intra-arterial, and topical. These treatments are distributed through channels like hospital pharmacies, retail pharmacies, and online platforms, and are used by end users including hospitals, clinics, cancer centers, and research laboratories.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the healthcare sector, particularly in the supply of critical medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are facing higher costs for imported surgical instruments, imaging equipment, and consumables such as syringes and catheters, many of which have limited domestic alternatives. These increased costs are straining healthcare budgets, leading some providers to delay equipment upgrades or pass on expenses to patients. Additionally, tariffs on raw materials and components are disrupting the production of essential drugs and devices, causing supply chain bottlenecks. In response, the industry is diversifying sourcing strategies, boosting local manufacturing where possible, and advocating for tariff exemptions on life-saving medical products.

The metastatic prostate cancer market research report is one of a series of new reports from The Business Research Company that provides metastatic prostate cancer market statistics, including metastatic prostate cancer industry global market size, regional shares, competitors with a metastatic prostate cancer market share, detailed metastatic prostate cancer market segments, market trends and opportunities, and any further data you may need to thrive in the metastatic prostate cancer industry. This metastatic prostate cancer market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The metastatic prostate cancer market size has grown strongly in recent years. It will grow from $8.11 billion in 2024 to $8.81 billion in 2025 at a compound annual growth rate (CAGR) of 8.7%. The growth during the historic period can be attributed to several factors, including a growing aging population, a rising incidence of prostate cancer, increased awareness and screening programs, advancements in diagnostic techniques, and higher healthcare expenditure.

The metastatic prostate cancer market size is expected to see strong growth in the next few years. It will grow to $12.16 billion in 2029 at a compound annual growth rate (CAGR) of 8.4%. The growth during the forecast period can be attributed to factors such as expanding screening initiatives, favorable reimbursement policies, increased adoption of advanced therapies, and market expansion in emerging economies. Key trends in the forecast period include advancements in diagnostic imaging technology, innovations in targeted therapies, developments in liquid biopsy, ongoing research and development in immunotherapy, and the adoption of minimally invasive surgical techniques.

The increasing demand for personalized treatments is expected to drive the growth of the metastatic prostate cancer market. Personalized treatments are medical approaches that are customized based on an individual's genetic profile, lifestyle, and disease characteristics to achieve more targeted and effective results. This demand is growing due to advancements in genomic profiling and biomarker testing, which help identify specific mutations and biological markers, allowing clinicians to choose therapies that are more likely to be effective for each patient. Personalized treatment strategies, such as biomarker-guided therapies and gene-targeted drugs, are revolutionizing the management of metastatic prostate cancer by matching therapies to each patient's specific tumor profile, improving effectiveness while minimizing side effects. For instance, the Personalized Medicine Coalition reported that in 2023, the US Food and Drug Administration (FDA) approved 16 new personalized treatments for rare diseases, up from just 6 in 2022. This rising demand for personalized approaches is fueling the growth of the metastatic prostate cancer market.

Key players in the metastatic prostate cancer market are focusing on developing advanced treatments like targeted radioligand therapy to improve treatment specificity, reduce damage to healthy tissues, and enhance patient outcomes. Targeted radioligand therapy is a precision cancer treatment that combines a molecule (ligand) designed to target specific cancer cells with a radioactive isotope that delivers localized radiation to destroy those cells. For example, in March 2022, Novartis AG, a Swiss pharmaceutical company, received FDA approval for Pluvicto, the first targeted radioligand therapy for prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer. This therapy uses lutetium-177, a radioactive isotope, linked to a ligand targeting PSMA, a protein found in high levels on prostate cancer cells, enabling precise radiation delivery. Pluvicto represents a breakthrough in prostate cancer treatment, significantly extending progression-free survival in patients who have run out of other treatment options.

In June 2024, AstraZeneca PLC, a UK-based biopharmaceutical company, acquired Fusion Pharmaceuticals for $2.4 billion. With this acquisition, AstraZeneca aims to strengthen its next-generation radioconjugate platform and accelerate the development of targeted cancer therapies, particularly for metastatic castration-resistant prostate cancer and other solid tumors. Fusion Pharmaceuticals is a Canadian clinical-stage company focused on targeted therapies, including a potential treatment for metastatic castration-resistant prostate cancer (mCRPC).

Major players in the metastatic prostate cancer market are Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Bayer AG, Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, Astellas Pharma Inc., Ipsen Group, Exelixis Inc., Ferring Pharmaceuticals, Dendreon Pharmaceuticals LLC, Hinova Pharmaceuticals Inc., Janux Therapeutics Inc., Zenith Epigenetics Ltd., Tavanta Therapeutics Inc., Cardiff Oncology Inc., Oncternal Therapeutics Inc., Clarity Pharmaceuticals Ltd., and Convergent Therapeutics Inc.

North America was the largest region in the metastatic prostate cancer market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in metastatic prostate cancer report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the metastatic prostate cancer market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The metastatic prostate cancer market consists of sales of radiopharmaceuticals, biosimilars, cancer pain management drugs, diagnostic imaging agents, and supportive care medications. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Metastatic Prostate Cancer Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on metastatic prostate cancer market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for metastatic prostate cancer ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The metastatic prostate cancer market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:1) By Treatment Type: Chemotherapy; Immunotherapy; Hormonal Therapy; Radiation Therapy; Other Treatments
2) By Route of Administration: Oral; Parenteral Route; Intravenous; Intrathecal; Intraperitoneal; Intra-Arterial; Topical
3) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Online Pharmacy; Other Distribution Channels
4) By End User: Hospitals; Clinics; Cancer Centers; Research Laboratories; Other End-Users
Subsegments:
1) By Chemotherapy: Docetaxel; Cabazitaxel; Mitoxantrone; Combination Chemotherapy Regimens
2) By Immunotherapy: Sipuleucel-T; Immune Checkpoint Inhibitors; Cancer Vaccines; Cytokine Therapies
3) By Hormonal Therapy: Luteinizing Hormone-Releasing Hormone (LHRH) Agonists; LHRH Antagonists; Anti-Androgens; Androgen Synthesis Inhibitors; Combined Androgen Blockade (CAB)
4) By Radiation Therapy: External Beam Radiation Therapy (EBRT); Stereotactic Body Radiotherapy (SBRT); Radiopharmaceutical Therapy; Intensity-Modulated Radiation Therapy (IMRT)
5) By Other Treatments: Targeted Therapy; Bone-Targeted Therapy; Clinical Trial Drugs; Palliative Therapy
Companies Mentioned: Pfizer Inc.; Merck & Co. Inc.; AbbVie Inc.; Bayer AG; Bristol-Myers Squibb Company; AstraZeneca PLC; Novartis AG; Astellas Pharma Inc.; Ipsen Group; Exelixis Inc.; Ferring Pharmaceuticals; Dendreon Pharmaceuticals LLC; Hinova Pharmaceuticals Inc.; Janux Therapeutics Inc.; Zenith Epigenetics Ltd.; Tavanta Therapeutics Inc.; Cardiff Oncology Inc.; Oncternal Therapeutics Inc.; Clarity Pharmaceuticals Ltd.; Convergent Therapeutics Inc.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.

Product Code: r37062

1. Executive Summary

2. Metastatic Prostate Cancer Market Characteristics

3. Metastatic Prostate Cancer Market Trends And Strategies

4. Metastatic Prostate Cancer Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Metastatic Prostate Cancer Growth Analysis And Strategic Analysis Framework

5.1. Global Metastatic Prostate Cancer PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Metastatic Prostate Cancer Market Growth Rate Analysis
5.4. Global Metastatic Prostate Cancer Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Metastatic Prostate Cancer Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Metastatic Prostate Cancer Total Addressable Market (TAM)

6. Metastatic Prostate Cancer Market Segmentation

6.1. Global Metastatic Prostate Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Chemotherapy
Immunotherapy
Hormonal Therapy
Radiation Therapy
Other Treatments
6.2. Global Metastatic Prostate Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Oral
Parenteral Route
Intravenous
Intrathecal
Intraperitoneal
Intra-Arterial
Topical
6.3. Global Metastatic Prostate Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Other Distribution Channels
6.4. Global Metastatic Prostate Cancer Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospitals
Clinics
Cancer Centers
Research Laboratories
Other End-Users
6.5. Global Metastatic Prostate Cancer Market, Sub-Segmentation Of Chemotherapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Docetaxel
Cabazitaxel
Mitoxantrone
Combination Chemotherapy Regimens
6.6. Global Metastatic Prostate Cancer Market, Sub-Segmentation Of Immunotherapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Sipuleucel-T
Immune Checkpoint Inhibitors
Cancer Vaccines
Cytokine Therapies
6.7. Global Metastatic Prostate Cancer Market, Sub-Segmentation Of Hormonal Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Luteinizing Hormone-Releasing Hormone (LHRH) Agonists
LHRH Antagonists
Anti-Androgens
Androgen Synthesis Inhibitors
Combined Androgen Blockade (CAB)
6.8. Global Metastatic Prostate Cancer Market, Sub-Segmentation Of Radiation Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
External Beam Radiation Therapy (EBRT)
Stereotactic Body Radiotherapy (SBRT)
Radiopharmaceutical Therapy
Intensity-Modulated Radiation Therapy (IMRT)
6.9. Global Metastatic Prostate Cancer Market, Sub-Segmentation Of Other Treatments, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Targeted Therapy
Bone-Targeted Therapy
Clinical Trial Drugs
Palliative Therapy

7. Metastatic Prostate Cancer Market Regional And Country Analysis

7.1. Global Metastatic Prostate Cancer Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Metastatic Prostate Cancer Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Metastatic Prostate Cancer Market

8.1. Asia-Pacific Metastatic Prostate Cancer Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Metastatic Prostate Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Metastatic Prostate Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Metastatic Prostate Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Metastatic Prostate Cancer Market

9.1. China Metastatic Prostate Cancer Market Overview
9.2. China Metastatic Prostate Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Metastatic Prostate Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Metastatic Prostate Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Metastatic Prostate Cancer Market

10.1. India Metastatic Prostate Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Metastatic Prostate Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Metastatic Prostate Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Metastatic Prostate Cancer Market

11.1. Japan Metastatic Prostate Cancer Market Overview
11.2. Japan Metastatic Prostate Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Metastatic Prostate Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Metastatic Prostate Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Metastatic Prostate Cancer Market

12.1. Australia Metastatic Prostate Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Metastatic Prostate Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Metastatic Prostate Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Metastatic Prostate Cancer Market

13.1. Indonesia Metastatic Prostate Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Metastatic Prostate Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Metastatic Prostate Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Metastatic Prostate Cancer Market

14.1. South Korea Metastatic Prostate Cancer Market Overview
14.2. South Korea Metastatic Prostate Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Metastatic Prostate Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Metastatic Prostate Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Metastatic Prostate Cancer Market

15.1. Western Europe Metastatic Prostate Cancer Market Overview
15.2. Western Europe Metastatic Prostate Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Metastatic Prostate Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Metastatic Prostate Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Metastatic Prostate Cancer Market

16.1. UK Metastatic Prostate Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Metastatic Prostate Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Metastatic Prostate Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Metastatic Prostate Cancer Market

17.1. Germany Metastatic Prostate Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Metastatic Prostate Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Metastatic Prostate Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Metastatic Prostate Cancer Market

18.1. France Metastatic Prostate Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Metastatic Prostate Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Metastatic Prostate Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Metastatic Prostate Cancer Market

19.1. Italy Metastatic Prostate Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Metastatic Prostate Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Metastatic Prostate Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Metastatic Prostate Cancer Market

20.1. Spain Metastatic Prostate Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Metastatic Prostate Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Metastatic Prostate Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Metastatic Prostate Cancer Market

21.1. Eastern Europe Metastatic Prostate Cancer Market Overview
21.2. Eastern Europe Metastatic Prostate Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Metastatic Prostate Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Metastatic Prostate Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Metastatic Prostate Cancer Market

22.1. Russia Metastatic Prostate Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Metastatic Prostate Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Metastatic Prostate Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Metastatic Prostate Cancer Market

23.1. North America Metastatic Prostate Cancer Market Overview
23.2. North America Metastatic Prostate Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Metastatic Prostate Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Metastatic Prostate Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Metastatic Prostate Cancer Market

24.1. USA Metastatic Prostate Cancer Market Overview
24.2. USA Metastatic Prostate Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Metastatic Prostate Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Metastatic Prostate Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Metastatic Prostate Cancer Market

25.1. Canada Metastatic Prostate Cancer Market Overview
25.2. Canada Metastatic Prostate Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Metastatic Prostate Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Metastatic Prostate Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Metastatic Prostate Cancer Market

26.1. South America Metastatic Prostate Cancer Market Overview
26.2. South America Metastatic Prostate Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Metastatic Prostate Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Metastatic Prostate Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Metastatic Prostate Cancer Market

27.1. Brazil Metastatic Prostate Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Metastatic Prostate Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Metastatic Prostate Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Metastatic Prostate Cancer Market

28.1. Middle East Metastatic Prostate Cancer Market Overview
28.2. Middle East Metastatic Prostate Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Metastatic Prostate Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Metastatic Prostate Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Metastatic Prostate Cancer Market

29.1. Africa Metastatic Prostate Cancer Market Overview
29.2. Africa Metastatic Prostate Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Metastatic Prostate Cancer Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Metastatic Prostate Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Metastatic Prostate Cancer Market Competitive Landscape And Company Profiles

30.1. Metastatic Prostate Cancer Market Competitive Landscape
30.2. Metastatic Prostate Cancer Market Company Profiles
- 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis

31. Metastatic Prostate Cancer Market Other Major And Innovative Companies

31.1. AstraZeneca PLC
31.2. Novartis AG
31.3. Astellas Pharma Inc.
31.4. Ipsen Group
31.5. Exelixis Inc.
31.6. Ferring Pharmaceuticals
31.7. Dendreon Pharmaceuticals LLC
31.8. Hinova Pharmaceuticals Inc.
31.9. Janux Therapeutics Inc.
31.10. Zenith Epigenetics Ltd.
31.11. Tavanta Therapeutics Inc.
31.12. Cardiff Oncology Inc.
31.13. Oncternal Therapeutics Inc.
31.14. Clarity Pharmaceuticals Ltd.
31.15. Convergent Therapeutics Inc.

32. Global Metastatic Prostate Cancer Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Metastatic Prostate Cancer Market

34. Recent Developments In The Metastatic Prostate Cancer Market

35. Metastatic Prostate Cancer Market High Potential Countries, Segments and Strategies

35.1 Metastatic Prostate Cancer Market In 2029 - Countries Offering Most New Opportunities
35.2 Metastatic Prostate Cancer Market In 2029 - Segments Offering Most New Opportunities
35.3 Metastatic Prostate Cancer Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer